MRUS
Price:
$45.485
Market Cap:
$3.11B
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients ...[Read more]
Industry
Biotechnology
IPO Date
2016-05-19
Stock Exchange
NASDAQ
Ticker
MRUS
According to Merus N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 8.32. This represents a change of 15.32% compared to the average of 7.22 of the last 4 quarters.
The mean historical Current Ratio of Merus N.V. over the last ten years is 5.84. The current 8.32 Current Ratio has changed 14.15% with respect to the historical average. Over the past ten years (40 quarters), MRUS's Current Ratio was at its highest in in the March 2017 quarter at 17.02. The Current Ratio was at its lowest in in the March 2015 quarter at 0.
Average
5.84
Median
5.68
Minimum
0.46
Maximum
10.05
Discovering the peaks and valleys of Merus N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.09%
Maximum Annual Current Ratio = 10.05
Minimum Annual Increase = -84.16%
Minimum Annual Current Ratio = 0.46
Year | Current Ratio | Change |
---|---|---|
2023 | 5.34 | 37.49% |
2022 | 3.88 | -34.19% |
2021 | 5.90 | 26.51% |
2020 | 4.66 | -30.65% |
2019 | 6.72 | -0.41% |
2018 | 6.75 | -32.81% |
2017 | 10.05 | 9.57% |
2016 | 9.17 | 67.84% |
2015 | 5.46 | 1.09% |
2014 | 0.46 | -84.16% |
The current Current Ratio of Merus N.V. (MRUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
5.04
5-year avg
5.30
10-year avg
5.84
Merus N.V.’s Current Ratio is greater than Anebulo Pharmaceuticals, Inc. (3.45), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (12.75), less than AnaptysBio, Inc. (10.23), less than Mineralys Therapeutics, Inc. (8.55), less than Crinetics Pharmaceuticals, Inc. (16.38), greater than Inhibrx Biosciences, Inc. (4.70), less than Lyell Immunopharma, Inc. (13.43), greater than Kronos Bio, Inc. (8.32), less than Kura Oncology, Inc. (11.47), less than Protagonist Therapeutics, Inc. (10.70), less than Replimune Group, Inc. (10.11), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Vaxcyte, Inc. (17.88), less than Larimar Therapeutics, Inc. (13.10), greater than Syndax Pharmaceuticals, Inc. (6.99), greater than Sutro Biopharma, Inc. (3.09),
Company | Current Ratio | Market cap |
---|---|---|
3.45 | $40.20M | |
2.50 | $96.95M | |
12.75 | $209.55M | |
10.23 | $732.72M | |
8.55 | $624.60M | |
16.38 | $5.30B | |
4.70 | $218.59M | |
13.43 | $263.05M | |
8.32 | $56.73M | |
11.47 | $850.73M | |
10.70 | $2.42B | |
10.11 | $992.23M | |
10.22 | $8.19B | |
17.88 | $11.60B | |
13.10 | $387.94M | |
6.99 | $1.44B | |
3.09 | $234.18M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Merus N.V.'s Current Ratio?
How is the Current Ratio calculated for Merus N.V. (MRUS)?
What is the highest Current Ratio for Merus N.V. (MRUS)?
What is the 3-year average Current Ratio for Merus N.V. (MRUS)?
What is the 5-year average Current Ratio for Merus N.V. (MRUS)?
How does the current Current Ratio for Merus N.V. (MRUS) compare to its historical average?